Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody
CHENGDU, China, May 12, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for PD-1 x VEGF bispecific antibody...
GenScript Launches TurboCHO™ Protein Expression Kit, Delivering the Fastest Path to Antibodies in its Class
New kit offers researchers and development teams a meaningful advance in expression speed and output BOSTON, May 13, 2026 /PRNewswire/ -- GenScript Biotech Corporation announced the launch of TurboCHO™ Protein Expression Kit, a next-generation antibody expression reagent designed to set a new benchmark for speed, performance, output and ease-of-use. One of the...
Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China
CRANBURY, N.J. and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Porton Advanced, a premier contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), and Dark Horse Consulting Group ("DHCG" or "the Group"), a leader in strategic and operational biotherapeutics consulting, recently announced the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration...
Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine
Isomorphic Labs will use the funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline. LONDON, May 12, 2026 /PRNewswire/ -- Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $2.1 Billion in Series B funding. This latest round of investment will accelerate the company's...
Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer
European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and no treatment-related serious adverse events in ESA-refractory lower-risk MDS Dr. Myint, a hematology leader and oncology drug-development executive, joins Halia to lead clinical development as ofirnoflast (HT-6184) advances toward pivotal trials LEHI, Utah, May 12, 2026 /PRNewswire/...
Insilico Medicine and Ribo Enter Strategic Collaboration Agreement: Leveraging AI Platform and Automated Lab for End-to-End Empowerment of RNA Interference and Oligonucleotide Therapeutics Development
SHANGHAI, May 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a biotechnology company powered by generative artificial intelligence, today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK), a globally leading clinical-stage company in oligonucleotide therapeutics. Building upon the automation, intelligence and scalability capabilities of Insilico's LifeStar 2 laboratory,...
Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI
SUZHOU, China, May 12, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine ("Insilico", 03696.HK). Both parties will leverage their respective core strengths in siRNA drug development and AI-powered drug discovery to conduct in-depth collaboration in...
Avance Clinical Receives Frost & Sullivan’s 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership
The company is recognized for its innovation, scientific expertise, and customer-centric clinical development model in the global biotechnology CRO market SAN ANTONIO, May 12, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce that Avance Clinical has been awarded the 2026 Global Company of the Year Recognition in the biotechnology contract research organization (CRO) industry for its outstanding achievements...
New Data Show Gaps in Antiviral Pipeline Against High-Risk Viral Threats
Longitudinal analysis reveals clear gaps in global preparedness against emerging viral threats and future pandemics. CAMBRIDGE, Mass., May 12, 2026 /PRNewswire/ -- New global analysis of antiviral compounds released today has identified a critically thin pipeline of treatments in development that target some of the 14 viral families with the greatest pandemic...
HKSH Medical Group Named Asia’s first Photon-Counting CT Simulator Reference Site, Bringing Global Impacts on Precision Medicine and Medical Imaging with Siemens Healthineers
HONG KONG, May 12, 2026 /PRNewswire/ -- HKSH Medical Group (HKSH) and global medical technology leader Siemens Healthineers today signed a collaboration agreement at the "Asia Summit on Global Health", establishing HKSH as Siemens Healthineers' first Photon‑Counting Computed Tomography Simulator (PCCT‑Sim) Reference Site in Asia. For driving the development of PCCT-Sim technology, HKSH is not only Siemens Healthineers' research...
